• Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, Szilagyi PG, Edwards KM, Staat MA, Hall CB, Durigon EL, Erdman DD. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015 Apr;65. 26-31. PMID: 25766983 [PubMed].


Respiratory syncytial virus (RSV) is a major cause of respiratory infections in children. Palivizumab (PZ) is the only RSV-specific immunoprophylaxis approved by the U.S. Food and Drug Administration. Mutations leading to amino acid substitutions in the PZ binding site of the RSV F protein have been associated with breakthrough RSV infections in patients receiving PZ.